For the chart of the week we wanted to explore the market for multi-analyte panels.  We found that single biomarker tests still vastly outnumber panels.  Stay tuned for more trending information in the coming weeks.  My hypothesis: Panels, even outside of NGS, are being introduced to the market faster than single biomarker tests.


Share this Image On Your Site

<p><strong>Please include attribution to with this graphic.</strong><br /><br /><a href=’’><img src=’’ alt=’Biomarker Counts in Diagnostic Tests’ width=’540px’ border=’0′ /></a></p>

For a refresher on Amplion and BiomarkerBase:

[plsc_button url=”″ target=”_blank” color=”green” style=”flat” radius=”square” size=”lg”]REQUEST DEMO[/plsc_button]